Cytyc Sees NovaSure, FirstCyte As Key Growth Opportunities Through 2008
Cytyc believes its NovaSure menorrhagia treatment will surpass Johnson & Johnson'sThermachoice as the top-selling endometrial ablation device within the next three years
Cytyc believes its NovaSure menorrhagia treatment will surpass Johnson & Johnson'sThermachoice as the top-selling endometrial ablation device within the next three years